Updated efficacy and safety results from ALTA, a randomized phase 2 trial of brigatinib in crizotinib-refractory ALK plus NSCLC

Authors :: Hochmair, M.
Ahn, M-J
Camidge, D. R.
Tiseo, M.
Reckamp, K.
Hansen, Holmskov K.
Kim, S-W
Huber, R.
West, H.
Groen, H.
Leighl, N.
Gettinger, S.
Langer, C.
Paz-Ares Rodriguez, L.
Smit, E.
Kim, E.
Reichmann, W.
Kerstein, D.
Kim, D-W
Source :: Oncology Research and Treatment, 41(Suppl.4):V849, 271-271. KARGER, Hochmair, M, Ahn, M-J, Camidge, D R, Tiseo, M, Reckamp, K, Hansen, H K, Kim, S-W, Huber, R, West, H, Groen, H, Leighl, N, Gettinger, S, Langer, C, Paz-Ares Rodriguez, L, Smit, E, Kim, E, Reichmann, W, Kerstein, D & Kim, D-W 2018, ' Updated efficacy and safety results from ALTA, a randomized phase 2 trial of brigatinib in crizotinib-refractory ALK plus NSCLC ', Oncology Research and Treatment, vol. 41, no. Suppl. 4, pp. 271 .
Publication Year :: 2018

Language :: English
ISSN :: 22965270
Database :: OpenAIRE
Journal :: Oncology Research and Treatment, 41(Suppl.4):V849, 271-271. KARGER, Hochmair, M, Ahn, M-J, Camidge, D R, Tiseo, M, Reckamp, K, Hansen, H K, Kim, S-W, Huber, R, West, H, Groen, H, Leighl, N, Gettinger, S, Langer, C, Paz-Ares Rodriguez, L, Smit, E, Kim, E, Reichmann, W, Kerstein, D & Kim, D-W 2018, ' Updated efficacy and safety results from ALTA, a randomized phase 2 trial of brigatinib in crizotinib-refractory ALK plus NSCLC ', Oncology Research and Treatment, vol. 41, no. Suppl. 4, pp. 271 .
Accession number :: edsair.dedup.wf.001..14a4e52a8201d69c462c533cfb0be9fd

Tools